Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2022

Share-based Payment Arrangement [Abstract]

Schedule of Stock Options Activity

The following summarizes the Company’s stock option activity for the six months ended June 30, 2022:

	Options Outstanding
	Number of Shares			Weighted Average Exercise Price		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding – December 31, 2021		10,027,094		$	3.28		7.2	$	67,173
Granted (a)		6,076,103		2.21
Exercised		(1,575,984	)	0.35
Cancelled		(943,681	)	6.52
Outstanding – June 30, 2022		13,583,532		$	2.92	7.2		$	15,828
Exercisable – December 31, 2021		5,176,464		$	0.46	5.3		$	49,268
Exercisable – June 30, 2022		7,859,849		$	0.91	5.8		$	14,748

(a) In connection with the acquisition of RE2, the Company assumed certain outstanding options to acquire RE2 common stock which, following such assumption, were converted to rights to acquire 3.9 million shares of the Company's common stock at a weighted-average exercise price of $1.05 per share.

Summary of RSU and RSA Activity

The following summarizes the Company’s RSU activity for the six months ended June 30, 2022:

	Restricted Stock Units Outstanding
	Number of Shares			Weighted-Average Grant-Date Fair Value
Outstanding – December 31, 2021		1,797,474		$	8.34
Granted		2,464,180		3.91
Released		(825,280	)	8.69
Cancelled		(235,776	)	8.52
Outstanding – June 30, 2022		3,200,598		$	4.83

The following summarizes the Company’s RSA activity for the six months ended June 30, 2022:

	Restricted Stock Awards Outstanding
	Number of Shares			Weighted-Average Grant-Date Fair Value
Outstanding – December 31, 2021		5,129,222		$	8.78
Granted		26,865			5.83
Released		(2,591,476	)		8.75
Outstanding – June 30, 2022		2,564,611		$	8.78

Schedule of Stock Based Compensation Expense

The Company recognized stock-based compensation expense in the condensed consolidated statement of operations and comprehensive loss as follows:

	For the three months ended June 30,				For the six months ended June 30,
(In thousands)	2022		2021		2022		2021
Cost of revenue	$	24	$	15	$	38	$	43
Research and development		159		73		314		134
Sales and marketing		251		12		383		22
General and administrative		9,836		119		20,385		193
Total stock-based compensation expense	$	10,270	$	219	$	21,120	$	392